This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mazzulli, T Articles by Low, D E Search for Related Content PubMed PubMed Citation Articles by Mazzulli, T Articles by Low, D E

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1990 March; 34(3): 467-469

Comparative in vitro activities of several new fluoroquinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae.

T Mazzulli, A E Simor, R Jaeger, S Fuller and D E Low

Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada.

ABSTRACT

The in vitro susceptibilities of 551 community isolates of Streptococcus pneumoniae from the Canadian province of Ontario to several new fluoroquinolones and beta-lactam antimicrobial agents were determined by a broth microdilution technique. Eight (1.5%) of these isolates were moderately susceptible (MICs, greater than or equal to 0.12 and less than or equal to 1.0 microgram/ml) to penicillin; none was resistant. Temafloxacin, ciprofloxacin, and ofloxacin (MICs for 90% of strains tested, between 1 and 2 micrograms/ml) were the most active fluoroquinolones tested, and BMY-28100 (MIC for 90% of strains tested, 0.25 microgram/ml) was the most active of the new beta-lactams tested.

---

Antimicrob Agents Chemother. 1990 March; 34(3): 467-469

This article has been cited by other articles:

• Zhanel, G. G., Johanson, C., Hisanaga, T., Mendoza, C., Laing, N., Noreddin, A., Wierzbowski, A., Hoban, D. J. (2004). Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations. J Antimicrob Chemother 54: 1072-1077 [Abstract] [Full Text]  
• Zhanel, G. G., DeCorby, M., Noreddin, A., Mendoza, C., Cumming, A., Nichol, K., Wierzbowski, A., Hoban, D. J. (2003). Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. J Antimicrob Chemother 52: 83-88 [Abstract] [Full Text]  
• Noreddin, A. M., Roberts, D., Nichol, K., Wierzbowski, A., Hoban, D. J., Zhanel, G. G. (2002). Pharmacodynamic Modeling of Clarithromycin against Macrolide-Resistant [PCR-Positive mef(A) or erm(B)] Streptococcus pneumoniae Simulating Clinically Achievable Serum and Epithelial Lining Fluid Free-Drug Concentrations. Antimicrob. Agents Chemother. 46: 4029-4034 [Abstract] [Full Text]  
• Jetté, L. P., Delage, G., Ringuette, L., Allard, R., De Wals, P., Lamothe, F., Loo, V., the Pneumococcus Study Group, (2001). Surveillance of Invasive Streptococcus pneumoniae Infection in the Province of Quebec, Canada, from 1996 to 1998: Serotype Distribution, Antimicrobial Susceptibility, and Clinical Characteristics. J. Clin. Microbiol. 39: 733-737 [Abstract] [Full Text]  
• Zhanel, G. G., Karlowsky, J. A., Palatnick, L., Vercaigne, L., Low, D. E., The Canadian Respiratory Infection Study Group, , Hoban, D. J. (1999). Prevalence of Antimicrobial Resistance in Respiratory Tract Isolates of Streptococcus pneumoniae: Results of a Canadian National Surveillance Study. Antimicrob. Agents Chemother. 43: 2504-2509 [Abstract] [Full Text]  
• Friedland, I. R., McCracken, G. H. (1994). Management of Infections Caused by Antibiotic-Resistant Streptococcus Pneumoniae. NEJM 331: 377-382 [Full Text]  
• Paker, G. E., Graham, J. A., Rauch, A. M., Collins, J. J. (1994). Cefuroxime Axetil in the Treatment of Sinusitis: A Review. Arch Fam Med 3: 165-175 [Abstract]  
• Caputo, G. M., Appelbaum, P. C., Liu, H. H. (1993). Infections due to Penicillin-Resistant Pneumococci: Clinical, Epidemiologic, and Microbiologic Features. Arch Intern Med 153: 1301-1310 [Abstract]